947673-12-3

Usage

Type of compound

chemical compound, derivative of piperazine

Functional group

phenylmethyl ester

Uses

pharmaceutical research, building block in the synthesis of various organic compounds, production of several pharmaceutical drugs, preparation of various heterocyclic compounds

Medicinal properties

potential affinity for certain receptors in the brain

Importance

considered an important intermediate in the production of several pharmaceutical drugs

Upstream product

• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 350-46-9 4-Fluoronitrobenzene 
• 501-53-1 benzyl chloroformate 
• 67455-41-8 4-(piperazin-1-yl)aniline 
• 947673-13-4 benzyl 4-(4-nitrophenyl)piperazine-1-carboxylate 

Downstream Products

• 1092069-33-4 C₂₀H₂₅N₃O 
• 1092069-92-5 C₂₀H₂₅N₃O₂ 
• 1092065-47-8 C₂₈H₃₀ClN₃O₃ 
• 1092065-46-7 C₂₉H₂₉Cl₂N₃O₂ 
• 1092069-07-2 C₂₇H₂₉ClN₄O₃ 
• 1092069-04-9 C₂₈H₂₉Cl₂N₃O₃ 
• 1092065-39-8 C₂₉H₃₃BrN₄O₂ 
• 1092065-40-1 C₂₉H₃₁ClN₄O₃ 
• 1092069-34-5 CH₄O₃S*C₁₉H₂₃N₃O₂ 
• 1092069-94-7 C₃₂H₃₇ClN₄O₅ 
• 1092065-41-2 C₂₈H₂₇Cl₂F₃N₄O₃ 
• 1092067-85-0 N-[2,6-dichloro-4-(pyrrolidin-1-ylmethyl)phenyl]4-(4-{[(4-methoxyphenyl)-acetyl]amino}phenyl)piperazine-1-carboxamide 
• 1092068-66-0 C₃₁H₃₅Cl₂N₅O₄ 
• 1092068-68-2 C₃₁H₃₅Cl₂N₅O₅ 

Relevant academic research and scientific papers

FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS

The disclosure provides compounds of formula (I), or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.

Imidazole derivatives, its pharmaceutical composition and use thereof

Imidazolone compounds, pharmaceutically acceptable salts, solvates, polymorphs or prodrugs thereof are disclosed. Pharmaceutical compositions comprising above substances and uses for preventing and treating protein kinases related diseases, such as cancers, metabolic diseases, cardiovascular diseases and the like, are also disclosed.

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.

Pyrrolopyrimidinyl axl kinase inhibitors

Compounds represented by Formula (I): are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with Axl kinase. The compounds can be formulated as pharmaceutically acceptable compositions for administration t

PIPERIDINE/PIPERAZINE DERIVATIVES

The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -C(=O)-; -O-C(=O)-; -C(=O)-C(=O)-; -NRx-C(=O)-; -Z1-C(O)-; -Z1-NRx-C(=O)-; -C(=O)-Z1-; -NRx-C(=O)-Z1-; -S(=O)p-; -C(=S)-; -NRx-C(=S)-; -Z1-C(=S)-; -Z1-NRX-C(=S)-; -C(=S)-Z1-; -NRx-C(=S)-Z1-; Y represents NRx-C(=0)- Z2-; -NRx-C(=0)-Z2-NRy-; -NRx-C(=0)-Z2-NRy-C(=0)-; -NRx-C(=0)-Z2-NRy-C(=0)- O-; -NRx-C(=0)-Z2-0-; -NRx-C(=0)-Z2-0-C(=0)-; -NRx-C(=0)-Z2-C(=0)-; -NRx-C(=0)-Z2-C(=0)-0-; -NRx-C(=0)-0-Z2-C(=0)-; -NRx-C(=0)-0-Z2-C(=0)-0-; -NRx-C(=O)-O-Z2-O-C(=O)-; -NRx-C(=O)-Z2-C(=O)-NRy-; -NRx-C(=O)-Z2-NRy- C(=0)-NRy-; -C(=O)-Z2-; -C(=O)-Z2-O-; -C(=0)-NRx-Z2-; -C(=0)-NRx-Z2-0-; -C(=0)-NRx-Z2-C(=0)-0-; -C(=0)-NRx-Z2-0-C(=0)-; -C(=0)-NRx-0-Z2-; -C(=O)- NRx-Z2-NRy-; -C(=0)-NRx-Z2-NRy-C(=0)-; -C(=0)-NRx-Z2-NRy-C(=0)-0-; R1 represents C1-12alkyl optionally substituted with cyano, C1-4alkyloxy, C1-4alkyl-oxyC1-4alkyloxy, C3-6Cy cloalkyl or aryl; C2-6alkenyl; C2-6alkynyl; C3-6cycloalkyl; adamantanyl; aryl1; aryl1C1-6alkyl; Het1; or Het1C1-6alkyl; provided that when Y represents -NRX-C(=O)-Z2-; -NRx-C(=0)-Z2-NRy; -NRX-C(=O)-Z2-C(=O)- NRy-; -C(=O)-Z2-; -NRx-C(=0)-Z2-NRy-C(=0)-NRy-; -C(=O)-NRX-Z2-; -C(=O)-NRX- O-Z2-; or -C(=0)-NRx-Z2-NRy-; then R1 may also represent hydrogen; R2 represents hydrogen, C1-12alkyl, C2-6alkenyl or R3; provided that if X represents -O-C(=O)-, then R2 represents R3; and provided that is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

PIPERIDINE/PIPERAZINE DERIVATIVES

The invention relates to a DGAT inhibitor of formula (I) including any stereochemically isomeric form thereof, wherein A represents CH or N; X represents O or NRx; the dotted line represents an optional bond in case A represents a carbon atom;

New Compounds

The present invention encompasses compounds of general formula (1) wherein R1 to R6, X and Y are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, as well as the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.